Introduction
Antibody-mediated rejection (AMR) is the major cause of late kidney transplant failure [2, 3] . While some patients presenting with donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) develop either chronic or acute AMR and ultimately reject their allograft, others maintain stable functioning allografts and continue to demonstrate normal biopsy histopathologies. In this study [1] , we sought to determine if any differences in gene expression between DSA +/AMR + patients, DSA +/AMR− patients, and DSA − controls might explain this phenomenon.
Study population
The study population consisted of 263 patients who underwent anti-HLA antibody testing at the time of biopsy for worsening kidney function and/or proteinuria. Antibody presence was detected using Luminex HLA Single Antigen Bead assays (LABScreen, One Lambda, Canoga Park, CA) with a mean fluorescence intensity (MFI) N= 1000 used as a cutoff for identification of DSA + patients. Demographic and clinical characteristics, as well as Banff histopathology scores [4] for these patients are shown in Table 1 
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Quality control, exploratory analysis, and linear modeling
For both biopsy and blood samples separately, raw probe intensities from Affymetrix Human Gene 1.0-ST array CEL files were background corrected, quantile normalized, and median-polish summarized using the robust multiarray average (RMA) method from the R/Bioconductor (http://www.bioconductor.org) oligo package [5] . Normalization of probe intensities was visualized using density plots (Fig. 1) . Annotation information was obtained from the Human Gene 1.0 transcript cluster database, hugene10sttranscriptcluster.db, and control probes were removed. Exploratory data analysis using both heatmaps based on between-sample Pearson correlation coefficient as well as multidimensional scaling plots (shown in Fig. 1 ) indicated that samples from the three clinical phenotypes were largely overlapping. Differences in gene expression were determined using the limma package [6] to fit gene-wise linear models to log2 scaled data with a Benjamini-Hochberg-corrected p-value cutoff of 0.01 and a log-odds probability of differential expression (B-statistic) greater than zero. As shown in Fig. 2 , the vast majority of individual gene expression changes identified in each of the sample group comparisons were relatively small (b1.5 fold change).
Gene ontology and gene-set enrichment analysis
Gene ontology (GO) analysis was performed using the GOstats package [7] , which carries out a hypergeometric test for enrichment of transcripts in specifically defined categories corresponding to distinct molecular functions or biological processes. In DSA +/AMR− biopsy samples, enrichment of genes related to cytokine production, including those involved in activation and regulation of type I interferon (alphaand beta-interferon) was observed relative to DSA − samples, while DSA+/AMR+ samples showed enrichment relative to DSA− samples of genes implicated in all aspects of the immune response, including those pertaining to the regulation and activation of T-cells and B-cells, natural killer cells, leukocytes, and cytokine production. Genes involved in the activation, regulation, and differentiation of T cells, natural killer cells, leukocytes, and interleukins were also enriched in DSA+/AMR+ whole-blood samples when compared to DSA +/AMR − samples. DSA+/AMR− blood samples however, did not show any enrichment of genes related to immune response when compared with DSA − controls.
We also carried out a gene-set analysis using both human-specific gene-sets derived from the Broad's MSigDB [8] by researchers at the Walter and Eliza Hall Institute's Bioinformatics Division (available for download at http://bioinf.wehi.edu.au/software/MSigDB/), as well as custom gene-sets created from groups of previously described pathogenesis-based transcripts (PBTs) which have been shown to be useful in molecular classification of antibody-mediated rejection [9] . The custom PBT gene-sets (detailed in Table 3 ) were generated by mapping the genes listed at the University of Alberta's Transplant Applied Table 2 Expression profiling study design.
Biopsy Blood DSA+/AMR+ n = 28 n = 28 DSA+/AMR− n = 13 n = 14 DSA− n = 20 n = 12
Genomics Center (http://transplants.med.ualberta.ca/Nephlab/data/ gene_lists.html) to HUGO gene identifiers and then converting to standard GMT format. The enrichment analysis was carried out using the limma romer function which implements a parametric re-sampling approach to gene-set enrichment analysis suitable for use with linear models. In biopsy samples, GRIT, CAT1, NKAT, CMAT, DSAST, and ENDAT transcripts were found to be significantly up-regulated in both DSA+/AMR+ and DSA+/AMR− samples relative to DSA− controls, while GRIT and DSAST transcripts were also expressed at significantly higher levels in DSA+/AMR+ biopsies compared to DSA+/AMR− biopsies (Fig. 3) . BAT and AMA transcripts were up-regulated in the DSA+/AMR− group relative to DSA− controls but not in the DSA+/ In DSA+/AMR+ samples, CAT, CMAT, and AMA transcript were upregulated compared to DSA− controls, while AMA and DSAST transcripts were also up-regulated compared to the DSA+/AMR− group.
Discussion
These results indicate that while some DSA+/AMR− biopsies retain normal histopathologies, they do however show increased levels of rejection-associated transcripts, including those related to interferon, T-cell, B-cell, natural killer cell, and macrophage function. Despite this increased level of rejection-associated transcripts, during a three-year follow-up, only four patients (17%) developed AMR while nine (43%) lost their DSA, highlighting the need for further study to develop a more complete understanding of the mechanisms of allograft protection. The analysis of whole-blood gene expression showed an increased immune response in DSA+/AMR+, but not in DSA+/AMR− patients, suggesting an ongoing immune response in the allograft rather than a systematic immune response.
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